Article | December 12, 2024

Strike The Balance Between Cost-Effective And Risk-Averse Biologic Manufacturing

Source: Mabion

By Nigel Stapleton, VP of Business Development, Head of Europe; Adam Pietruszkiewicz, Chief Commercial Officer; and Marty Henehan, VP of Business Development, Head of North America

Risk-Reward-GettyImages-1247884241

In the push to accommodate an increasingly global pharmaceutical market, drug sponsors are working to strike the ever-delicate balance between risk mitigation, speed to market, and high product quality. Though outsourcing to the Asia-Pacific region has long been a popular option for U.S. and European drug sponsors, recent geopolitical tensions and supply chain challenges are leading many to consider the benefits of partnering with a domestic or allied CDMO to manufacture their biologic.

While domestic and allied partnerships can help sponsors avoid risks to IP, supply chain delays, and potential tariffs, drug sponsors must be strategic to find capacity from said partners. To secure a manufacturing slot with a U.S. or European CDMO, it is important to start discussions with potential partners as early as possible. The sooner you find the right partner, the sooner your biologic will be on track to reaching patients.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development